Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from CTI BioPharma and Incyte Corporation.

Community Practice Connections®: Advancing Polycythemia Vera and Myelofibrosis: An Expert Tumor Board Discussion

Release Date: January 31, 2019
Expiration Date: January 31, 2020
Media: Internet - based

Activity Overview

The activity reviews diagnostic considerations and prognostic assessments in myeloproliferative neoplasms (MPNs), including polycythemia vera (PV) and essential thrombocythemia. This program discusses diagnosis, contemporary methods of prognostic assessment, standards of MPN management, the evolving MPN treatment landscape, and the role of stem cell transplant in MPN management. Case-based discussions and question-and answer sessions contextualize the didactic information in a tumor board discussion format. This program also provides a forum for panelists to evaluate the latest clinical data, compare practice patterns, and discuss best practices in patient management with colleagues.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from CTI BioPharma and Incyte Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational program is directed toward hematologists, medical oncologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with MPNs. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the diagnosis and treatment of patients with hematologic malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  1. Describe the pathogenesis and molecular characteristics of MPNs that influence the development of novel therapeutics for MF and PV
  2. Discuss the current treatment landscape for MF and PV and why they share common therapies
  3. Evaluate clinical data on emerging agents and regimens to treat MF and PV and their implications for routine practice
  4. Develop an evidence-based treatment plan to improve outcomes in the treatment of MPNs

Faculty, Staff, and Planners' Disclosures


Ronald Hoffman, MD
Albert A. and Vera G. List Professor of Medicine
Director, Myeloproliferative Disorders Research Program
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant/Research Support: Incyte, Novartis, Formation Biologics, Scholar Rock, Janssen; Consultant: Novartis.

Nicolaus Kröger
Nicolaus Kröger, MD
Professor of Medicine
Medical Director, Department of Stem Cell Transplantation
University Medical Center Hamburg-Eppendorf
Hamburg, Germany

Disclosures: Grant/Research Support: Novartis; Other: Novartis (Lecture Honorarium).

Michael J. Mauro
Michael J. Mauro, MD
Leader, Myeloproliferative Neoplasms Program, Leukemia Service
Member, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York, NY

Disclosures: Grant/Research Support: Novartis Oncology; Consultant: Novartis Oncology, Bristol-Myers Squibb, Pfizer, Ariad.

Brady Lee Stein
Brady Lee Stein, MD
Associate Professor of Medicine
Feinberg School of Medicine
Northwestern University
Chicago, IL

Disclosures: Consultant: Apexx Oncology (Incyte 2 years prior).

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By